AcuityMD raised US$80 million in its Series C funding round this month. The round brought the its valuation close to US$1 billion.
Investors included StepStone Group as the leader, along with Benchmark, Redpoint Ventures, ICONIQ and Atreides Management.
This brings the Boston-based company’s total fundraising to date above US$160 million. The money lets AcuityMD add more advanced AI features to its sales software for medical device makers.
Teams can now get quicker insights on where to sell devices, which doctors to approach and how to plan their work. The goal is to help reps spend less time searching for data and more time closing deals that get new medical tools into hospitals and clinics faster.
Sales leaders at medical device makers often juggle massive amounts of scattered information about hospitals, doctors and procedures. The fresh capital gives AcuityMD room to grow its team and refine its tools so companies can bring new treatments to patients more efficiently.
Read more: Breath Diagnostics advances pre-op pneumonia screening with FDA breakthrough designation
Major medtech users served and potential fits
AcuityMD serves more than 400 medtech companies, including 16 of the top 20, according to the company. Larger operators use the platform to handle complex sales data across hospitals, surgery centres and health systems.
Kuros Biosciences AG (OTCMKTS: CSBTF) (FRA: YTSN) relies on it for bone graft products. Sales leaders there ask the AI tool for quick business plans on new contracts, including which surgeons to target and supporting context that once took hours of manual research to gather. Another, Beckton Dickinson and Co (NYSE: BDX) (FRA: BOX), applies the software when launching products or buying assets. Executives say it uncovers market opportunities they previously missed and helps convert pipeline into actual sales.
Additionally, Anika Therapeutics Inc (NASDAQ: ANIK) used AcuityMD’s platform to generate more than US$20 million in new pipeline opportunities through targeted insights on product launches. Teleflex Inc (NYSE: TFX) also counts among its notable clients, as do companies such as Enovis Corp (NYSE: ENOV) (FRA: C520) and SI-Bone Inc (NASDAQ: SIBN) (FRA: 2K3) in various case examples and announcements.
These established players turn to the tool because medtech sales involve dense data on procedures, physicians, contracts and patient claims. The platform organizes that information and delivers it in daily workflows, including mobile access for field reps.
Breath Diagnostics, which develops breath-based tests for early disease detection, could benefit from better targeting of specialists and hospital systems open to new diagnostic tools. Other startups working on novel implants, robotics or monitoring devices often struggle with limited sales resources. They might use such software to identify high-potential accounts.
Trading on the Nasdaq Private Market
AcuityMD shares trade on the this exclusive exchange. The venue allows accredited investors to buy and sell stock in private companies that have not yet gone public. It gives early backers and employees a way to gain liquidity or adjust holdings before any IPO while the company stays private and focuses on growth.
Other AI and medtech firms also appear there. Companies developing healthcare analytics, sales tools or device-related software sometimes list shares to attract institutional capital without the regulatory demands of public markets.
The setup reflects broader trends in private tech investing. Medtech and AI startups often stay private longer amid high development costs and regulatory timelines. Secondary markets like this provide flexibility for stakeholders, though trading remains limited to qualified investors and prices can fluctuate based on limited activity.
AcuityMD’s presence there signals strong interest from sophisticated players who follow its progress in commercial intelligence for medical devices.
Read more: Prestigious medtech intelligence firm recognizes Breath Diagnostics for innovation
Follow Rowan Dunne on LinkedIn
rowan@mugglehead.com
